Skip to main content
Evotec secures second FDA clearance under Bristol Myers Squibb partnership
Image for illustrative purposes only. Not a real photo.

Evotec secures second FDA clearance under Bristol Myers Squibb partnership

By

Key points

  • Evotec announced a second FDA clearance for an Investigational New Drug (IND) application under its protein degradation partnership with Bristol Myers Squibb, allowing another experimental candidate targeting cereblon to enter clinical development.
  • The newly cleared candidate is expected to enter Phase 1 trials in 2027, expanding the companies' clinical pipeline in targeted protein degradation.
  • The partnership's first candidate entered Phase 1 in March 2026 for advanced clear cell renal cell carcinoma, building on a collaboration established in 2018 and expanded in 2022.

Evotec SE (NASDAQ:EVO) announced that the U.S. Food and Drug Administration (FDA) has accepted a second Investigational New Drug (IND) application under its strategic protein degradation partnership with Bristol Myers Squibb (NYSE:BMY), advancing another experimental drug candidate toward clinical development.

The newly accepted candidate is a cereblon E3 ligase modulator (CELMoD), a type of molecular glue degrader designed to promote the selective degradation of disease-associated proteins.

Evotec expects the candidate to enter a Phase 1 clinical trial in 2027.

"The progression of a second molecular glue candidate to IND acceptance demonstrates the repeatability and productivity of our discovery platform," said Dr. Joanna Holbrook, chief scientific officer of Evotec.

The announcement follows the advancement of the partnership's first candidate, which entered a Phase 1 clinical trial in March 2026 for patients with advanced clear cell renal cell carcinoma, the most common form of kidney cancer.

The collaboration began in 2018 with Celgene, which was subsequently acquired by Bristol Myers Squibb, and was expanded in 2022 to support the discovery and development of molecular glue degraders for oncology and other therapeutic areas.

Under the partnership, Evotec contributes its PanOmics and PanHunter platforms, high-throughput proteomics and AI-supported drug discovery capabilities, while Bristol Myers Squibb provides its library of cereblon E3 ligase modulators.

The collaboration aims to identify and advance experimental medicines targeting proteins that may be difficult to address through conventional drug development approaches.

The second IND acceptance represents another development milestone for the partnership, although the candidate must still undergo clinical testing to establish its safety, tolerability and potential therapeutic effectiveness.


Frequently asked questions